Clinical Trial

Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder

Study acronym: BorderKET
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main objective of this pilot study is to evaluate at D9 the evolution of BPD symptoms' intensity(scale BSL-23) in severe BPD patients, after two Ketamine infusions (0.5mg/kg at H0 and H24). The intervention is combined with the first level standard of care : Good Psychiatric Management (GPM). Patients are followed up to 3 months by regular visits conducted by a psychiatrist. Secondary outcomes are monitored including BPD symptoms at different times, suicidal ideation, depressiv symptoms, healthcare use and adverse effects.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-25; most recent amendment 2026-05-07.
Trial Details
NCT Number NCT07099534
Lead Sponsor University Hospital, Toulouse
Conditions Infusion of Ketamine in Severe Borderline Personality Disorder, Borderline Personality Disorder (BPD)
Enrollment 38 participants
Start Date 2026-09-01
Primary Completion 2028-09-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-12